Compare TAYD & RNAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TAYD | RNAC |
|---|---|---|
| Founded | 1955 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.0M | 175.8M |
| IPO Year | N/A | 2016 |
| Metric | TAYD | RNAC |
|---|---|---|
| Price | $74.50 | $7.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $70.00 | $38.80 |
| AVG Volume (30 Days) | 27.7K | ★ 191.8K |
| Earning Date | 12-31-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.18 | N/A |
| EPS | ★ 3.01 | N/A |
| Revenue | ★ $47,647,810.00 | $1,091,000.00 |
| Revenue This Year | $10.81 | N/A |
| Revenue Next Year | $8.37 | N/A |
| P/E Ratio | $24.78 | ★ N/A |
| Revenue Growth | ★ 7.11 | N/A |
| 52 Week Low | $29.50 | $5.98 |
| 52 Week High | $75.00 | $20.12 |
| Indicator | TAYD | RNAC |
|---|---|---|
| Relative Strength Index (RSI) | 75.12 | 50.60 |
| Support Level | $66.40 | $7.18 |
| Resistance Level | $68.94 | $8.34 |
| Average True Range (ATR) | 3.08 | 0.56 |
| MACD | 0.54 | 0.06 |
| Stochastic Oscillator | 96.59 | 55.67 |
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.